<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298882</url>
  </required_header>
  <id_info>
    <org_study_id>DIADM2-001</org_study_id>
    <nct_id>NCT01298882</nct_id>
  </id_info>
  <brief_title>Diacerein on Insulin Secretion in Diabetes</brief_title>
  <official_title>Effect of Diacerein on Insulin Secretion in Patients With Type 2 Diabetes Mellitus and Overweight or Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim. To assess the effect of interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα)&#xD;
      inhibition with diacerein administration on insulin secretion and metabolic control of&#xD;
      drug-naïve patients with type 2 diabetes mellitus (T2DM) and overweight or obesity.&#xD;
&#xD;
      Hypothesis. Diacerein administration improves insulin secretion and metabolic control of&#xD;
      drug-naïve patients with type 2 diabetes mellitus (T2DM) and overweight or obesity.&#xD;
&#xD;
      Materials and methods. Design: Randomized, double-blind, placebo-controlled clinical trial.&#xD;
      Population: 40 drug-naïve adult patients with T2DM and overweight or obesity. Measurements: A&#xD;
      metabolic profile including IL-1β, TNFα, interleukin 6, and fasting insulin levels, as well&#xD;
      as, hyperglycemic-hyperinsulinemic clamp technique; to assess the phases of insulin secretion&#xD;
      and insulin sensitivity. Intervention for 2 mo: diacerein (50 mg once daily) for the first 15&#xD;
      days and twice daily for 45 additional days or placebo. Statistical analyses: Wilcoxon signed&#xD;
      rank and Mann-Whitney U test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting insulin concentration</measure>
    <time_frame>2 mo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose concentration</measure>
    <time_frame>2 mo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>A1C concentration</measure>
    <time_frame>2 mo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>First phase of insulin secretion</measure>
    <time_frame>2 mo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Late phase of insulin secretion</measure>
    <time_frame>2 mo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total insulin secretion concentration</measure>
    <time_frame>2 mo</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Diacerein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diacerein</intervention_name>
    <arm_group_label>Diacerein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fasting glucose levels between 7.0 and 11.1 mmol/L&#xD;
&#xD;
          -  A1C levels between 7 and 9%&#xD;
&#xD;
          -  Same residential area and socioeconomic status&#xD;
&#xD;
          -  Excessively sedentary or participated in heavy physical activity&#xD;
&#xD;
          -  Nonsmokers&#xD;
&#xD;
          -  Body weight was stable for at least 3 months before the study&#xD;
&#xD;
          -  Blood pressure was &lt;130/80 mm Hg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal history of hepatic, renal or coronary artery disease&#xD;
&#xD;
          -  Medications known to affect metabolism during the previous 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Unidad de Investigación Médica en Epidemiología Clínica</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44380</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Manuel González-Ortiz</name_title>
    <organization>CIS Mexico</organization>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diacetylrhein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

